CME Group (NASDAQ:CME – Free Report) had its price target lifted by Oppenheimer from $245.00 to $258.00 in a research report report published on Thursday, Benzinga reports. The brokerage currently has an outperform rating on the financial services provider’s stock.
CME has been the subject of a number of other research reports. TD Cowen started coverage on CME Group in a research report on Thursday, September 26th. They set a “hold” rating and a $221.00 price target for the company. Citigroup lifted their target price on CME Group from $250.00 to $255.00 and gave the stock a “buy” rating in a report on Thursday. Morgan Stanley increased their price target on shares of CME Group from $210.00 to $233.00 and gave the stock an “equal weight” rating in a report on Thursday, October 17th. Piper Sandler lifted their price objective on shares of CME Group from $225.00 to $240.00 and gave the company an “overweight” rating in a research note on Tuesday, October 8th. Finally, The Goldman Sachs Group increased their price objective on shares of CME Group from $195.00 to $198.00 and gave the stock a “sell” rating in a research note on Thursday, October 3rd. Four research analysts have rated the stock with a sell rating, seven have issued a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $222.07.
View Our Latest Stock Report on CME Group
CME Group Price Performance
CME Group (NASDAQ:CME – Get Free Report) last issued its quarterly earnings results on Wednesday, October 23rd. The financial services provider reported $2.68 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.65 by $0.03. The business had revenue of $1.58 billion for the quarter, compared to analyst estimates of $1.59 billion. CME Group had a net margin of 56.98% and a return on equity of 12.82%. CME Group’s revenue for the quarter was up 18.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.25 EPS. As a group, equities analysts forecast that CME Group will post 10.04 earnings per share for the current fiscal year.
CME Group Dividend Announcement
The company also recently announced a quarterly dividend, which was paid on Wednesday, September 25th. Shareholders of record on Monday, September 9th were issued a dividend of $1.15 per share. The ex-dividend date was Monday, September 9th. This represents a $4.60 dividend on an annualized basis and a dividend yield of 2.03%. CME Group’s payout ratio is currently 52.33%.
Insider Activity
In related news, CFO Lynne Fitzpatrick sold 754 shares of the stock in a transaction on Sunday, September 15th. The stock was sold at an average price of $216.99, for a total value of $163,610.46. Following the completion of the transaction, the chief financial officer now directly owns 13,261 shares of the company’s stock, valued at approximately $2,877,504.39. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CFO Lynne Fitzpatrick sold 754 shares of the company’s stock in a transaction on Sunday, September 15th. The shares were sold at an average price of $216.99, for a total transaction of $163,610.46. Following the completion of the sale, the chief financial officer now owns 13,261 shares of the company’s stock, valued at $2,877,504.39. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Bryan T. Durkin sold 7,593 shares of the firm’s stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $214.59, for a total transaction of $1,629,381.87. Following the completion of the transaction, the director now directly owns 55,607 shares in the company, valued at approximately $11,932,706.13. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.30% of the company’s stock.
Institutional Investors Weigh In On CME Group
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Salomon & Ludwin LLC purchased a new stake in CME Group in the 1st quarter valued at $28,000. Y.D. More Investments Ltd acquired a new position in shares of CME Group during the 2nd quarter valued at about $36,000. Thurston Springer Miller Herd & Titak Inc. grew its holdings in shares of CME Group by 62.2% in the third quarter. Thurston Springer Miller Herd & Titak Inc. now owns 193 shares of the financial services provider’s stock valued at $43,000 after purchasing an additional 74 shares during the period. McClarren Financial Advisors Inc. increased its position in CME Group by 66.1% during the second quarter. McClarren Financial Advisors Inc. now owns 196 shares of the financial services provider’s stock worth $39,000 after purchasing an additional 78 shares during the last quarter. Finally, Asset Dedication LLC raised its stake in CME Group by 515.2% during the second quarter. Asset Dedication LLC now owns 203 shares of the financial services provider’s stock worth $40,000 after purchasing an additional 170 shares during the period. Institutional investors and hedge funds own 87.75% of the company’s stock.
CME Group Company Profile
CME Group Inc, together with its subsidiaries, operates contract markets for the trading of futures and options on futures contracts worldwide. It offers futures and options products based on interest rates, equity indexes, foreign exchange, agricultural commodities, energy, and metals, as well as fixed income and foreign currency trading services.
Further Reading
- Five stocks we like better than CME Group
- Investing in the High PE Growth Stocks
- Real Estate Sector Outperforms: 3 Stocks to Gain Exposure
- What is the Nasdaq? Complete Overview with History
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- What Investors Need to Know to Beat the Market
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
Receive News & Ratings for CME Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CME Group and related companies with MarketBeat.com's FREE daily email newsletter.